A novel pro-drug overcomes short-half life and absorption challenges and increase brain penetration of dopamine as a potential therapy for Parkinson’s disease
Objective: We developed a new small molecule drug candidate that would increase the effectiveness of dopamine delivery to the brain. We also sought to mitigate…ALPHA-FIT: Slowing cognitive decline in alpha-synucleinopathies by enhancing physical activity
Objective: To evaluate the effects of increased physical activity on cognitive decline in patients with isolated REM sleep behavior disorder (iRBD). Background: Physical activity has…Patient-Derived α-Synuclein Kinetic Subtypes Drive Distinct Pathological Propagation Patterns and Brain Network Alterations in Parkinson’s Disease Mouse Models
Objective: To validate whether patient-derived α-synuclein (α-Syn) aggregates with distinct kinetic properties produce differentiated pathological propagation patterns, brain network functional alterations, and behavioral phenotypes in…The Syn-D Study: Detection of Longitudinal Changes in Cutaneous Phosphorylated Alpha-Synuclein in Mild Cognitive Impairment
Objective: To quantify the deposition of cutaneous phosphorylated alpha-synuclein (P-SYN) and plasma P-Tau217 in patients with mild cognitive impairment (MCI) due to suspected Alzheimer’s disease…Disassembly of α-Synuclein Aggregates by the All-D-peptide PRI-101: Preclinical Efficacy in Vitro and in Vivo.
Objective: To develop a disease-modifying therapy for Parkinson’s disease (PD) and related synucleinopathies by eliminating intracellular, toxic, and seeding-competent aggregate species of α-synuclein (α-syn). Background:…SCA27B and MSA-C with Positive Alpha-Synuclein Skin Biopsy – Case Report
Objective: To present the first reported case of Spinocerebellar Ataxia 27B (SCA27B) and clinically probable Multiple System Atrophy-Cerebellar subtype (MSA-C) with skin biopsy positive for alpha synuclein. Background: SCA27B is…Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate
Objective: Evaluate efficacy and biomarker response of ATH434 in MSA, including CSF neurofilament light chain (NfL), a prespecified but previously unreported analysis using this disease-severity…Identification of Alpha-synuclein Pathology in Primary Tauopathies by Seed Amplification Assay
Objective: To assess intravitam frequency and type of misfolded α-synuclein aggregates (syn-seeds) in participants with clinically defined primary tauopathies, such as progressive supranuclear palsy (PSP)…Clinical Evaluation of TT-P34: Exploring Safety and CSF Exposure in Parkinson’s Disease Patients
Objective: Evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT-P34 in cerebrospinal fluid (CSF) following multiple subcutaneous (SC) doses in Parkinson’s disease patients…The Syn-Sleep Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder
Objective: The goals of this study are to 1) determine rates of phosphorylated alpha-synuclein (P-SYN) deposition in iRBD, 2) quantify changes in P-SYN deposition over…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 70
- Next Page »